Is Addex Therapeutics ready for a correction?
 | By Vlad Skutelnik | Macroaxis Story |
In today's thesis, we are going to go over some ideas for Addex Therapeutics investors who consider a position in the company. We will inspect the possibilities of making Addex Therapeutics into a steady grower in August. Is Addex Therapeutics current valuation justified for 2020? Here i will cover my perspective on the firm valuation to give investors a better outlook on taking a position in the stock. What is Addex Therapeutics probability of distress for August 2020? What is Addex Therapeutics Target Price Odds to finish over Current Price? Proceeding from a normal probability distribution, the odds of Addex Therapeutics to move above the current price in 30 days from now is near 1%. The Addex Therapeutics probability density function shows the probability of Addex Therapeutics Stock to fall within a particular range of prices over 30 days. Given the investment horizon of 30 days, Addex Therapeutics has a beta of 0.277 . This suggests as returns on the market go up, Addex Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Addex Therapeutics will be expected to be much smaller as well. Moreover, the company has an alpha of 1.0334, implying that it can generate a 1.03 percent excess return over DOW after adjusting for the inherited market risk (beta).
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Rifka Kats
Addex Therapeutics currently holds 492.32 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest Addex Therapeutics is not taking enough advantage from borrowing. This firm currently holds 492.32 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the entity is not taking enough advantage from borrowing. The company has a current ratio of 4.9, suggesting that it is liquid enough and is able to pay its financial obligations when due. Addex Therapeutics is OVERVALUED at 9.68 per share with modest projections ahead. We determine the current worth of Addex Therapeutics using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Addex Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Addex Therapeutics's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Addex Therapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Addex Therapeutics. We calculate exposure to Addex Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Addex Therapeutics's related companies.
Addex Therapeutics Investment Alerts
Addex investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Addex Therapeutics performance across your portfolios.Please check all investment alerts for AddexAddex Therapeutics Valuation Ratios as Compared to Competition
Our valuation model uses many indicators to compare Addex value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Addex Therapeutics competition to find correlations between indicators driving the intrinsic value of Addex.Addex Therapeutics Gross Profit
Addex Therapeutics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Addex Therapeutics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Addex Therapeutics Gross Profit growth over the last 10 years. Please check Addex Therapeutics' gross profit and other fundamental indicators for more details.
Details
Addex Therapeutics shows a negative utilization of assets of -0.0024 percent, losing $2.4E-5 for each dollar of assets held by the firm. Unsuccessful asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way asset utilization of Addex Therapeutics shows how unproductive it operates for each dollar spent on its assets. Addex Therapeutics has a beta of 0.277. Let's try to break down what Addex's beta means in this case. As returns on the market increase, Addex Therapeutics returns are expected to increase less than the market. However, during the bear market, the loss on holding Addex Therapeutics will be expected to be smaller as well. The beta indicator helps investors understand whether Addex Therapeutics moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Addex deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. The latest price spikes of Addex Therapeutics could raise concerns from investors as the firm closed today at a share price of 10.44 on 283.00 in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in August. The stock standard deviation of daily returns for 30 days investing horizon is currently 11.99. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Addex Therapeutics partners. Addex Therapeutics Free Cash Flow is decreasing over the last 4 years. Also, Addex Therapeutics Earnings Before Interest Taxes and Depreciation Amortization USD is quite stable at the moment.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Addex Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.